Advertisement
Employment/Membership › Details
Sangamo–Lee S: management, 201910– CFO before 14 years at Gilead Sciences
Period | 2019-10-31 � 2021-01-06 | |
Successor | MorphoSys–Lee S: management, 202102–202303 CFO before Sangamo + Gilead Sciences LEFT 3/23 to return to US | |
Organisation | Sangamo Therapeutics Inc. (Nasdaq: SGMO) | |
Group | Sangamo (Group) | |
Organisation 2 | Gilead Sciences Inc. (Nasdaq: GILD) | |
Group | Gilead Sciences (Group) | |
Product | gene therapy | |
Product 2 | cell therapy | |
Person | Lee, Sung (MorphoSys 202102–202303 CFO before Sangamo + Gilead Sciences LEFT 3/23) | |
Sangamo Therapeutics, Inc.. (11/1/19). "Press Release: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer". Brisbane, CA.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019. Mr. Lee oversees finance, facilities and information technology functions for Sangamo and reports to the Chief Executive Officer.
“I am excited to welcome Sung to the leadership team and believe that his exceptional track record of improving operational performance, leading large teams, and communicating with investors, as well as his deep experience and success in financial planning and analysis, will have a significant impact on Sangamo as we continue to grow,” said Sandy Macrae, Sangamo's Chief Executive Officer.
Mr. Lee joins Sangamo from Gilead Sciences, where he spent nearly 14 years, most recently as Senior Vice President leading the financial planning & analysis (FP&A) and investor relations functions. In this dual capacity, he managed the global planning and budgeting process, drove process improvement, and managed all aspects of communications to the investor community. Prior to this role, Mr. Lee held roles of increasing responsibility at Gilead, including Head of Europe Finance and Head of R&D FP&A.
Mr. Lee received a B.A. in Economics from University of California, Irvine, and a M.B.T. from University of Southern California.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com
Forward-Looking Statements
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's anticipated growth as a clinical stage development company and into commercialization. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual and Quarterly Reports as filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
Investor Relations – Global
McDavid Stilwell
510-970-6000, x219
mstilwell@sangamo.com
Media Inquiries – Global
Aron Feingold
510-970-6000, x421
afeingold@sangamo.com
Investor Relations and Media Inquiries – European Union & United Kingdom
Caroline Courme
33 4 97 21 27 27
ccourme@sangamo.com
Record changed: 2021-01-08 |
Advertisement
More documents for Sangamo (Group)
- [1] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
- [2] Mogrify Ltd.. (4/21/20). "Press Release: Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-derived Regulatory T Cells". Cambridge & Brisbane, CA....
- [3] Sangamo Therapeutics, Inc.. (11/26/19). "Press Release: Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors". Brisbane, CA....
- [4] Sangamo Therapeutics, Inc.. (11/19/19). "Press Release: Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation". Brisbane, CA....
- [5] Sangamo Therapeutics, Inc.. (11/18/19). "Press Release: Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference". Brisbane, CA....
- [6] Sangamo Therapeutics, Inc.. (11/1/19). "Press Release: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer". Brisbane, CA....
- [7] Sangamo Therapeutics, Inc.. (9/30/19). "Press Release: Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences". Brisbane, CA....
- [8] Sangamo Therapeutics, Inc.. (7/31/19). "Press Release: Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel". Brisbane, CA....
- [9] Sangamo Therapeutics, Inc.. (4/8/19). "Press Release: Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares". Richmond, CA....
- [10] Sangamo Therapeutics, Inc.. (4/4/19). "Press Release: Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock". Richmond, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top